Merus (NASDAQ:MRUS – Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 318,828 shares were traded during trading, a decline of 43% from the previous session’s volume of 557,783 shares.The stock last traded at $39.87 and had previously closed at $43.85.
Analysts Set New Price Targets
MRUS has been the subject of several analyst reports. Guggenheim restated a “buy” rating and issued a $109.00 price objective (down previously from $111.00) on shares of Merus in a report on Tuesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 2nd. The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 9th. Finally, Citigroup boosted their target price on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $85.64.
Read Our Latest Stock Analysis on MRUS
Merus Trading Down 3.6 %
Merus (NASDAQ:MRUS – Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The firm had revenue of $11.77 million for the quarter, compared to the consensus estimate of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Equities research analysts forecast that Merus will post -3.89 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRUS. FMR LLC boosted its position in shares of Merus by 10.4% in the third quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock valued at $343,421,000 after acquiring an additional 648,994 shares during the period. Wellington Management Group LLP grew its position in shares of Merus by 73.6% during the 3rd quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after purchasing an additional 1,224,573 shares in the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Merus by 3.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,749,401 shares of the biotechnology company’s stock worth $162,682,000 after purchasing an additional 100,000 shares in the last quarter. Samlyn Capital LLC increased its holdings in shares of Merus by 11.9% during the second quarter. Samlyn Capital LLC now owns 2,324,195 shares of the biotechnology company’s stock worth $137,523,000 after purchasing an additional 247,605 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Merus by 7.1% in the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company’s stock valued at $117,722,000 after buying an additional 150,341 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.
About Merus
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
- Five stocks we like better than Merus
- Do ETFs Pay Dividends? What You Need to Know
- 3 REITs With Big Dividend Growth and Sustainable Payouts
- What Makes a Stock a Good Dividend Stock?
- Can Integrated Healthcare Stocks Succeed in Public Markets?
- Buy P&G Now, Before It Sets A New All-Time High
- What Lucid’s Partnership With SoundHound Means for LCID Stock
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.